118 related articles for article (PubMed ID: 23190516)
1. Alpha-galactosidase A activity levels in Turkish male hemodialysis patients.
Kalkan Uçar S; Sozmen E; Duman S; Başçi A; Çoker M
Ther Apher Dial; 2012 Dec; 16(6):560-5. PubMed ID: 23190516
[TBL] [Abstract][Full Text] [Related]
2. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype.
Nakao S; Kodama C; Takenaka T; Tanaka A; Yasumoto Y; Yoshida A; Kanzaki T; Enriquez AL; Eng CM; Tanaka H; Tei C; Desnick RJ
Kidney Int; 2003 Sep; 64(3):801-7. PubMed ID: 12911529
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel mutation and prevalence study for fabry disease in Japanese dialysis patients.
Nishino T; Obata Y; Furusu A; Hirose M; Shinzato K; Hattori K; Nakamura K; Matsumoto T; Endo F; Kohno S
Ren Fail; 2012; 34(5):566-70. PubMed ID: 22563919
[TBL] [Abstract][Full Text] [Related]
4. Fabry disease in hemodialysis patients in southern Brazil: prevalence study and clinical report.
Porsch DB; Nunes AC; Milani V; Rossato LB; Mattos CB; Tsao M; Netto C; Burin M; Pereira F; Matte U; Giugliani R; Barros EJ
Ren Fail; 2008; 30(9):825-30. PubMed ID: 18925518
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of Fabry disease among Turkish dialysis patients: Data from hemodialysis centers in Bursa province.
Sayilar EI; Ayar Y; Yavuz M
Clin Nephrol; 2016 Mar; 85(3):165-72. PubMed ID: 26833297
[TBL] [Abstract][Full Text] [Related]
6. Screening for Fabry disease in patients undergoing dialysis for chronic renal failure in Turkey: identification of new case with novel mutation.
Okur I; Ezgu F; Biberoglu G; Tumer L; Erten Y; Isitman M; Eminoglu FT; Hasanoglu A
Gene; 2013 Sep; 527(1):42-7. PubMed ID: 23756194
[TBL] [Abstract][Full Text] [Related]
7. Significance of screening for Fabry disease among male dialysis patients.
Ichinose M; Nakayama M; Ohashi T; Utsunomiya Y; Kobayashi M; Eto Y
Clin Exp Nephrol; 2005 Sep; 9(3):228-32. PubMed ID: 16189631
[TBL] [Abstract][Full Text] [Related]
8. Fabry disease in patients with end-stage renal failure: the potential benefits of screening.
Bekri S; Enica A; Ghafari T; Plaza G; Champenois I; Choukroun G; Unwin R; Jaeger P
Nephron Clin Pract; 2005; 101(1):c33-8. PubMed ID: 15886492
[TBL] [Abstract][Full Text] [Related]
9. Screening Fabry's disease in chronic kidney disease patients not on dialysis: a multicenter study.
Yeniçerioğlu Y; Akdam H; Dursun B; Alp A; Sağlam Eyiler F; Akın D; Gün Y; Hüddam B; Batmazoğlu M; Gibyeli Genek D; Pirinççi S; Ersoy İR; Üzüm A; Soypaçacı Z; Tanrısev M; Çolak H; Demiral Sezer S; Bozkurt G; Akyıldız UO; Akyüz Ünsal Aİ; Ünübol M; Uslu M; Eryılmaz U; Günel C; Meteoğlu İ; Yavaşoğlu İ; Ünsal A; Akar H; Okyay P
Ren Fail; 2017 Nov; 39(1):104-111. PubMed ID: 27832731
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of Fabry's disease within hemodialysis patients in Spain.
Herrera J; Miranda CS
Clin Nephrol; 2014 Feb; 81(2):112-20. PubMed ID: 24365053
[TBL] [Abstract][Full Text] [Related]
11. Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma.
Froissart R; Guffon N; Vanier MT; Desnick RJ; Maire I
Mol Genet Metab; 2003 Nov; 80(3):307-14. PubMed ID: 14680977
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of Fabry disease in young patients with cryptogenic ischemic stroke.
Dubuc V; Moore DF; Gioia LC; Saposnik G; Selchen D; Lanthier S
J Stroke Cerebrovasc Dis; 2013 Nov; 22(8):1288-92. PubMed ID: 23168217
[TBL] [Abstract][Full Text] [Related]
13. Targeted Screening of Fabry Disease in Male Hemodialysis Patients in Brazil Highlights Importance of Family Screening.
Silva CA; Barreto FC; Dos Reis MA; Moura Junior JA; Cruz CM
Nephron; 2016; 134(4):221-230. PubMed ID: 27576502
[TBL] [Abstract][Full Text] [Related]
14. Identification of Fabry's disease by the screening of alpha-galactosidase A activity in male and female hemodialysis patients.
Tanaka M; Ohashi T; Kobayashi M; Eto Y; Miyamura N; Nishida K; Araki E; Itoh K; Matsushita K; Hara M; Kuwahara K; Nakano T; Yasumoto N; Nonoguchi H; Tomita K
Clin Nephrol; 2005 Oct; 64(4):281-7. PubMed ID: 16240899
[TBL] [Abstract][Full Text] [Related]
15. Middelheim Fabry Study (MiFaS): a retrospective Belgian study on the prevalence of Fabry disease in young patients with cryptogenic stroke.
Brouns R; Sheorajpanday R; Braxel E; Eyskens F; Baker R; Hughes D; Mehta A; Timmerman T; Vincent MF; De Deyn PP
Clin Neurol Neurosurg; 2007 Jul; 109(6):479-84. PubMed ID: 17509753
[TBL] [Abstract][Full Text] [Related]
16. Detection of alpha-galactosidase a mutations causing Fabry disease by denaturing high performance liquid chromatography.
Shabbeer J; Robinson M; Desnick RJ
Hum Mutat; 2005 Mar; 25(3):299-305. PubMed ID: 15712228
[TBL] [Abstract][Full Text] [Related]
17. Kidney transplantation and enzyme alpha-galactosidase A therapy in patient with Fabry disease: a case report.
Dziemianko I; Jezior D; Boratyńska M; Patrzałek D; Kuźniar J; Szyber P; Klinger M
Transplant Proc; 2007 Nov; 39(9):2925-7. PubMed ID: 18022018
[TBL] [Abstract][Full Text] [Related]
18. A missense mutation, A156T, in the alpha-galactosidase A gene causes typical Fabry disease.
Konoshita T; Mutoh H; Yokoi T; Koni I; Miyamori I; Mabuchi H
Clin Nephrol; 2001 Mar; 55(3):243-7. PubMed ID: 11316246
[TBL] [Abstract][Full Text] [Related]
19. The Ckd. Qld fabRy Epidemiology (aCQuiRE) study protocol: identifying the prevalence of Fabry disease amongst patients with kidney disease in Queensland, Australia.
Mallett A; Kearey P; Cameron A; Healy H; Denaro C; Thomas M; Lee VW; Stark S; Fuller M; Hoy WE
BMC Nephrol; 2020 Feb; 21(1):58. PubMed ID: 32087678
[TBL] [Abstract][Full Text] [Related]
20. Fabry disease: results of the first UK hemodialysis screening study.
Wallin EF; Clatworthy MR; Pritchard NR
Clin Nephrol; 2011 Jun; 75(6):506-10. PubMed ID: 21612753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
